Form 4: Organon Executive Reports RSU Vesting and New Grant

Head of R&D and CMO Juan Camilo Arjona Ferreira reported the vesting of restricted stock units and a new equity grant.

Summary

• Juan Camilo Arjona Ferreira, Head of R&D and CMO of Organon & Co., exercised 13,431 restricted stock units (RSUs) on March 31, 2026.
• 4,820 shares were withheld to cover tax obligations at a price of $5.70 per share.
• The reporting person received a new grant of 200,333 RSUs on March 31, 2026.
• The new RSUs vest in three equal annual installments starting March 31, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which does not signal a change in company fundamentals.

Positives

• The executive maintains a significant equity stake in the company, aligning interests with shareholders.
• The new RSU grant serves as a long-term retention incentive for a key member of the R&D leadership team.

Negatives

• The transaction involved a tax-related sell-to-cover, which is a standard administrative procedure but reduces the net share increase for the executive.

Risks

• Future value of the equity is subject to market volatility and the company's ability to execute its R&D pipeline.

Future Outlook

The filing indicates a long-term commitment from the Head of R&D, with new equity vesting through 2029.

Management Comments

• No direct management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that routine equity compensation filings for pharmaceutical executives are standard practice and generally reflect internal confidence in long-term R&D milestones.

Comparison to Industry Standards

• The use of RSUs as a primary component of executive compensation is consistent with industry standards for large-cap pharmaceutical companies.
• The three-year vesting schedule for new grants is standard practice for retaining senior leadership in the biotech and pharma sectors.

Stakeholder Impact

• Shareholders may view the long-term equity grant as a positive sign of management retention.

Next Steps

• Vesting of the first tranche of the new 200,333 RSU grant on March 31, 2027.

Key Dates

Keywords

Organon, OGN, Form 4, Insider Trading, Equity Compensation, R&D